Discontinued Product1,9-Dideoxyforskolin (Cat. No. 5034) has been withdrawn from sale for commercial reasons.
Inactive analog of forskolin (Cat. No. 1099); does not activate adenylyl cyclase.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
References are publications that support the biological activity of the product.
Wadler and Wiernik (1988) Partial reversal of doxorubicin resistance by forskolin and 1,9-dideoxyforskolin in murine sarcoma S180 variants. Cancer Res. 48 539 PMID: 2825978
McHugh and McGee (1986) Direct anesthetic-like effects of forskolin on the nicotinic acetylcholine receptors of PC12 cells. J.Biol.Chem. 261 3103 PMID: 3005280
Keywords: 1,9-Dideoxyforskolin, 1,9-Dideoxyforskolin supplier, inactive, analogs, analogues, forskolin, adenylyl, adenylate, cyclases, Adenylyl, Cyclase, 5034, Tocris Bioscience
Citations for 1,9-Dideoxyforskolin
Citations are publications that use Tocris products.
Currently there are no citations for 1,9-Dideoxyforskolin.
Reviews for 1,9-Dideoxyforskolin
There are currently no reviews for this product. Be the first to review 1,9-Dideoxyforskolin and earn rewards!
Have you used 1,9-Dideoxyforskolin?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.